Title: SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes.
Journal: Toxicology and applied pharmacology 20140615
Title: p53 and NF-κB coregulate proinflammatory gene responses in human macrophages.
Journal: Cancer research 20140415
Title: Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Journal: Molecular cancer 20140101
Title: SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
Journal: Investigational new drugs 20121201
Title: An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis.
Journal: Journal of proteome research 20121102
Title: The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Journal: Haematologica 20121101
Title: DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity.
Journal: Cell death and differentiation 20121101
Title: A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Journal: Haematologica 20121101
Title: Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Journal: Bioorganic & medicinal chemistry letters 20121015
Title: Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.
Journal: Blood 20121011
Title: Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.
Journal: Cancer biology & therapy 20120901
Title: A novel function of p53: a gatekeeper of retinal detachment.
Journal: The American journal of pathology 20120901
Title: Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.
Journal: Cancer 20120901
Title: Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Journal: The Journal of biological chemistry 20120831
Title: MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120815
Title: Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.
Journal: Investigational new drugs 20120801
Title: The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome.
Journal: The British journal of dermatology 20120801
Title: Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.
Journal: Cancer biology & therapy 20120801
Title: The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Journal: Nucleic acid therapeutics 20120801
Title: Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Journal: Cancer research 20120715
Title: Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Journal: Neuro-oncology 20120701
Title: ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
Journal: Nature chemical biology 20120701
Title: The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.
Journal: Cell cycle (Georgetown, Tex.) 20120701
Title: Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Journal: Veterinary immunology and immunopathology 20120630
Title: Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.
Journal: Oncogene 20120607
Title: Chk2 mediates RITA-induced apoptosis.
Journal: Cell death and differentiation 20120601
Title: Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes.
Journal: Molecular cancer research : MCR 20120601
Title: Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Journal: Molecular carcinogenesis 20120501
Title: Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.
Journal: Journal of cellular physiology 20120501
Title: Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
Journal: Leukemia 20120501
Title: p53 and MDM2 are involved in the regulation of osteocalcin gene expression.
Journal: Experimental cell research 20120501
Title: An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.
Journal: Cell cycle (Georgetown, Tex.) 20120501
Title: Reversible induction of PARP1 degradation by p53-inducible cis-imidazoline compounds.
Journal: Biochemical and biophysical research communications 20120427
Title: The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation.
Journal: Human immunology 20120401
Title: Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.
Journal: Cell cycle (Georgetown, Tex.) 20120401
Title: Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Journal: Cell death & disease 20120401
Title: Structural insights into the dual-targeting mechanism of Nutlin-3.
Journal: Biochemical and biophysical research communications 20120330
Title: Arsenite-induced apoptosis of human neuroblastoma cells requires p53 but occurs independently of c-Jun.
Journal: Neuroscience 20120329
Title: MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.
Journal: Neuroscience letters 20120328
Title: Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Journal: Oncogene 20120301
Title: Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Journal: Cancer 20120215
Title: MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Journal: Oncogene 20120209
Title: Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Journal: Investigational new drugs 20120201
Title: p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.
Journal: The Journal of investigative dermatology 20120201
Title: Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Journal: Biochemical and biophysical research communications 20120120
Title: Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium.
Journal: BMC women's health 20120101
Title: Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance.
Journal: PloS one 20120101
Title: p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Journal: PloS one 20120101
Title: Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3.
Journal: PloS one 20120101
Title: HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.
Journal: Journal of hematology & oncology 20120101
Title: 2,3,7,8-Tetrachlorodibenzo-p-dioxin's suppression of 1-nitropyrene-induced p53 expression is mediated by cytochrome P450 1A1.
Journal: Chemical research in toxicology 20111219
Title: MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Journal: Stem cells (Dayton, Ohio) 20111201
Title: Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.
Journal: Journal of drug targeting 20111201
Title: Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Journal: Cell death & disease 20111201
Title: Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
Journal: Oncogene 20111117
Title: Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.
Journal: Cardiovascular research 20110901
Title: Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110901
Title: The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
Journal: Cell cycle (Georgetown, Tex.) 20110715
Title: MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
Journal: Biochemical pharmacology 20110701
Title: A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.
Journal: Neoplasia (New York, N.Y.) 20110701
Title: Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
Journal: Cell death & disease 20110701
Title: Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.
Journal: Cancer research 20110615
Title: Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
Journal: European journal of cancer (Oxford, England : 1990) 20110601
Title: Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.
Journal: Molecular cancer therapeutics 20110601
Title: Mechanism-specific signatures for small-molecule p53 activators.
Journal: Cell cycle (Georgetown, Tex.) 20110515
Title: Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy.
Journal: Chemical biology & drug design 20110501
Title: Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.
Journal: Investigative ophthalmology & visual science 20110501
Title: miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110501
Title: Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Journal: Leukemia 20110501
Title: Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
Journal: Cell death & disease 20110501
Title: Synthetic protocol published for promising anticancer compound.
Journal: Future medicinal chemistry 20110501
Title: An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts.
Journal: Biochemical and biophysical research communications 20110415
Title: Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Journal: Cell death & disease 20110401
Title: Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.
Journal: Nanomedicine (London, England) 20110401
Title: Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Journal: Journal of medicinal chemistry 20110310
Title: Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
Journal: Blood 20110303
Title: Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Journal: Cancer science 20110301
Title: Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.
Journal: Oncotarget 20110301
Title: HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications.
Journal: Anticancer research 20110301
Title: Suppression of p53 activity through the cooperative action of Ski and histone deacetylase SIRT1.
Journal: The Journal of biological chemistry 20110225
Title: Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110215
Title: Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins.
Journal: Journal of the American Chemical Society 20110209
Title: Nutlin-3a is a potential therapeutic for ewing sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110201
Title: MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Journal: Journal of gastroenterology and hepatology 20110201
Title: Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.
Journal: Acta biomaterialia 20110101
Title: Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Journal: Apoptosis : an international journal on programmed cell death 20110101
Title: p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma.
Journal: Oral oncology 20110101
Title: Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation.
Journal: Journal of medicinal food 20110101
Title: A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.
Journal: BMC cancer 20110101
Title: Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
Journal: Current pharmaceutical design 20110101
Title: Recent advances in the therapeutic perspectives of Nutlin-3.
Journal: Current pharmaceutical design 20110101
Title: Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
Journal: PloS one 20110101
Title: p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.
Journal: PloS one 20110101
Title: MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
Journal: Molecular cancer 20110101
Title: MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Journal: BMC cancer 20110101
Title: Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.
Journal: PloS one 20110101
Title: Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.
Journal: Molecular cancer 20110101
Title: Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.
Journal: PloS one 20110101
Title: MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
Journal: Cancer letters 20101228
Title: p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.
Journal: Pigment cell & melanoma research 20101201
Title: mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Journal: Aging 20101201
Title: Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Journal: Molecular cancer therapeutics 20101201
Title: DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Journal: Aging 20101201
Title: Hypoxia downregulates p53 but induces apoptosis and enhances expression of BAD in cultures of human syncytiotrophoblasts.
Journal: American journal of physiology. Cell physiology 20101101
Title: Shifting senescence into quiescence by turning up p53.
Journal: Cell cycle (Georgetown, Tex.) 20101101
Title: Weak p53 permits senescence during cell cycle arrest.
Journal: Cell cycle (Georgetown, Tex.) 20101101
Title: p53: The pivot between cell cycle arrest and senescence.
Journal: Cell cycle (Georgetown, Tex.) 20101101
Title: The p53 inducing drug dosage may determine quiescence or senescence.
Journal: Aging 20101101
Title: Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
Journal: Oncotarget 20101101
Title: p53-dependent repression of polo-like kinase-1 (PLK1).
Journal: Cell cycle (Georgetown, Tex.) 20101015
Title: Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Journal: Journal of cancer research and clinical oncology 20101001
Title: HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
Journal: The Journal of biological chemistry 20100917
Title: Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Journal: Cancer biology & therapy 20100915
Title: Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
Journal: Cell death and differentiation 20100901
Title: Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20100801
Title: The C terminus of p53 binds the N-terminal domain of MDM2.
Journal: Nature structural & molecular biology 20100801
Title: Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Journal: Assay and drug development technologies 20100801
Title: Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
Journal: British journal of cancer 20100713
Title: MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.
Journal: British journal of haematology 20100701
Title: Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
Journal: Cancer science 20100601
Title: Decision-making by p53 and mTOR.
Journal: Aging 20100601
Title: The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
Journal: Aging 20100601
Title: Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Journal: Apoptosis : an international journal on programmed cell death 20100501
Title: 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
Journal: Molecular cancer therapeutics 20100501
Title: Role of Mdm4 in drug sensitivity of breast cancer cells.
Journal: Oncogene 20100422
Title: Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Journal: European urology 20100401
Title: Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
Journal: Cell cycle (Georgetown, Tex.) 20100401
Title: Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines.
Journal: Anticancer research 20100401
Title: The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100315
Title: Foxp3 expression in p53-dependent DNA damage responses.
Journal: The Journal of biological chemistry 20100312
Title: Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Journal: Journal of pharmaceutical and biomedical analysis 20100311
Title: Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli.
Journal: Cellular signalling 20100301
Title: Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
Journal: British journal of haematology 20100301
Title: Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction.
Journal: Journal of neurochemistry 20100301
Title: DNA damage response to the Mdm2 inhibitor nutlin-3.
Journal: Biochemical pharmacology 20100215
Title: The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.
Journal: Leukemia 20100201
Title: Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
Journal: Cancer letters 20100101
Title: Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
Journal: Leukemia 20100101
Title: Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.
Journal: BMC cancer 20100101
Title: Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.
Journal: BMC cancer 20100101
Title: High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity.
Journal: Oncology reports 20091201
Title: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091201
Title: Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Journal: Journal of the National Cancer Institute 20091118
Title: Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Journal: Investigative ophthalmology & visual science 20091001
Title: Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Journal: Carcinogenesis 20091001
Title: Awakening p53 in senescent cells using nutlin-3.
Journal: Aging 20091001
Title: Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
Journal: Aging 20091001
Title: Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Journal: The Journal of biological chemistry 20090925
Title: Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Journal: Leukemia 20090901
Title: Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.
Journal: Cell cycle (Georgetown, Tex.) 20090901
Title: MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Journal: British journal of cancer 20090901
Title: Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.
Journal: Molecular cancer therapeutics 20090901
Title: HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Journal: Cancer research 20090801
Title: Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090615
Title: Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
Journal: Current cancer drug targets 20090601
Title: The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Journal: International journal of oncology 20090501
Title: Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Journal: Blood 20090430
Title: Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
Journal: Leukemia 20090401
Title: Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.
Journal: Cancer research 20090401
Title: Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction.
Journal: Cancer letters 20090318
Title: Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
Journal: Molecular cancer therapeutics 20090301
Title: The essential role of p53 in hyperpigmentation of the skin via regulation of paracrine melanogenic cytokine receptor signaling.
Journal: The Journal of biological chemistry 20090213
Title: MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090201
Title: Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Journal: Cancer research 20090115
Title: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Journal: Annual review of pharmacology and toxicology 20090101
Title: Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.
Journal: The Journal of biological chemistry 20081107
Title: Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
Journal: Leukemia 20081101
Title: MDM2 E3 ubiquitin ligase mediates UT-A1 urea transporter ubiquitination and degradation.
Journal: American journal of physiology. Renal physiology 20081101
Title: RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.
Journal: Cell cycle (Georgetown, Tex.) 20081101
Title: Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
Journal: Blood 20081001
Title: E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Journal: Oncogene 20080911
Title: The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
Journal: Leukemia 20080901
Title: Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation.
Journal: Cell cycle (Georgetown, Tex.) 20080801
Title: A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Journal: Leukemia 20080701
Title: BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death.
Journal: Cell cycle (Georgetown, Tex.) 20080701
Title: Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response.
Journal: International journal of radiation oncology, biology, physics 20080601
Title: Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
Journal: Journal of the American Chemical Society 20080521
Title: Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Journal: Journal of cellular biochemistry 20080515
Title: Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Journal: Cancer research 20080501
Title: Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
Journal: Molecular cancer therapeutics 20080501
Title: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Journal: Blood 20080401
Title: MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
Journal: Leukemia 20080401
Title: Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.
Journal: Molecular cancer therapeutics 20080401
Title: HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Journal: Oncogene 20080207
Title: Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
Journal: Journal of leukocyte biology 20080201
Title: Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells.
Journal: Blood 20080201
Title: Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
Journal: Ethnicity & disease 20080101
Title: Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2.
Journal: Journal of pharmaceutical and biomedical analysis 20071221
Title: p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
Journal: Cancer research 20071015
Title: MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071001
Title: The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
Journal: Neoplasia (New York, N.Y.) 20071001
Title: Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20070901
Title: Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.
Journal: Cell cycle (Georgetown, Tex.) 20070901
Title: Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.
Journal: Cell death and differentiation 20070701
Title: Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.
Journal: The Prostate 20070601
Title: Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070601
Title: Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Journal: Current drug metabolism 20070501
Title: Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.
Journal: Leukemia 20070401
Title: Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Journal: Cancer research 20070401
Title: [TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
Journal: Medecine sciences : M/S 20070401
Title: Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.
Journal: The Journal of biological chemistry 20070126
Title: Antiangiogenic activity of the MDM2 antagonist nutlin-3.
Journal: Circulation research 20070105
Title: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.
Journal: Cancer cell 20061201
Title: Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Journal: Cell cycle (Georgetown, Tex.) 20061201
Title: Hdmx modulates the outcome of p53 activation in human tumor cells.
Journal: The Journal of biological chemistry 20061103
Title: Cancer biology: second step to retinal tumours.
Journal: Nature 20061102
Title: Inactivation of the p53 pathway in retinoblastoma.
Journal: Nature 20061102
Title: Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.
Journal: Cancer research 20061101
Title: Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.
Journal: Biochemical pharmacology 20061016
Title: Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Journal: Cancer research 20061001
Title: Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20060901
Title: MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Journal: Molecular cancer therapeutics 20060901
Title: Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Journal: Blood 20060801
Title: A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.
Journal: Biochemistry 20060801
Title: (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Journal: Experimental cell research 20060715
Title: The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein methyltransferases and is required for G1-S transition.
Journal: Cancer research 20060615
Title: Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
Journal: Blood 20060515
Title: MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
Journal: Blood 20060515
Title: An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
Journal: Nature chemical biology 20060401
Title: Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Journal: Cancer research 20060315
Title: WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.
Journal: The Journal of biological chemistry 20051230
Title: Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.
Journal: Blood 20051115
Title: MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Journal: Blood 20051101
Title: Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy.
Journal: Journal of the American Chemical Society 20050928
Title: Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.
Journal: The Journal of biological chemistry 20041217
Title: Yu Z, et al. Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors. Int J Mol Sci. 2014 Sep 5;15(9):15741-53.
Title: Zhang Y, et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.Cancer Biol Ther. Cancer Biol Ther. 2012 Aug;13(10):915-24.
Title: Supiot S, et al. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008 Apr;7(4):993-9.
